Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recent Advancements in Cell-Based Therapies in Melanoma.
Nassief G, Anaeme A, Moussa K, Mansour AN, Ansstas G. Nassief G, et al. Among authors: ansstas g. Int J Mol Sci. 2024 Sep 12;25(18):9848. doi: 10.3390/ijms25189848. Int J Mol Sci. 2024. PMID: 39337333 Free PMC article. Review.
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.
Hughes BGM, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, Grob JJ, Lewis KD, Ansstas G, Day F, Ladwa R, Stein BN, Muñoz Couselo E, Meier F, Hauschild A, Schadendorf D, Basset-Seguin N, Modi B, Dalac-Rat S, Dunn LA, Flatz L, Mortier L, Guégan S, Heinzerling LM, Mehnert JM, Trabelsi S, Soria-Rivas A, Stratigos AJ, Ulrich C, Wong DJ, Beylot-Barry M, Bossi P, Bugés Sánchez C, Chandra S, Robert C, Russell JS, Silk AW, Booth J, Yoo SY, Seebach F, Lowy I, Fury MG, Rischin D. Hughes BGM, et al. Among authors: ansstas g. J Am Acad Dermatol. 2025 Jan;92(1):68-77. doi: 10.1016/j.jaad.2024.06.108. Epub 2024 Sep 7. J Am Acad Dermatol. 2025. PMID: 39245360 Clinical Trial.
A Phase 1/2 Study of Disulfiram and Copper With Concurrent Radiation Therapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma.
Huang J, Campian JL, DeWees TA, Skrott Z, Mistrik M, Johanns TM, Ansstas G, Butt O, Leuthardt E, Dunn GP, Zipfel GJ, Osbun JW, Abraham C, Badiyan S, Schwetye K, Cairncross JG, Rubin JB, Kim AH, Chheda MG. Huang J, et al. Among authors: ansstas g. Int J Radiat Oncol Biol Phys. 2024 Nov 1;120(3):738-749. doi: 10.1016/j.ijrobp.2024.05.009. Epub 2024 May 19. Int J Radiat Oncol Biol Phys. 2024. PMID: 38768767 Clinical Trial.
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Weber JS, et al. Among authors: ansstas g. Lancet. 2024 Feb 17;403(10427):632-644. doi: 10.1016/S0140-6736(23)02268-7. Epub 2024 Jan 18. Lancet. 2024. PMID: 38246194 Clinical Trial.
PARP inhibition and immunotherapy: a promising duo in fighting cancer.
Phillipps J, Zhou AY, Butt OH, Ansstas G. Phillipps J, et al. Among authors: ansstas g. Transl Cancer Res. 2023 Sep 30;12(9):2433-2437. doi: 10.21037/tcr-23-726. Epub 2023 Aug 3. Transl Cancer Res. 2023. PMID: 37859734 Free PMC article. No abstract available.
58 results